Disease-associated antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2

Xaquín Castro Dopico[1][#], Leo Hanke[1][°], Daniel J. Sheward[1][°], Murray Christian[1], Sandra Muschiol[2], Nastasiya F. Grinberg[3], Monika Adori[1], Laura Perez Vidakovics[1], Kim Chang Il[1], Sharesta Khoenkhoen[1], Pradeepa Pushparaj[1], Ainhoa Moliner Morro[1], Marco Mandolesi[1], Mattias Forsell[4], Jonathan Coquet[1], Martin Corcoran[1], Joanna Rorbach[5,6], Soo Aleman[7], Gordana Bogdanovic[2], Gerald McInerney[1], Tobias Allander[1,2], Chris Wallace[3,8], Ben Murrell[1][*], Jan Albert[1,2][*], Gunilla B. Karlsson Hedestam[1][#]

Affiliations:
[1]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
[2]Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
[3]Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
[4]Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
[5]Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden
[6]Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
[7]Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
[8]MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom

[°][*]Equal contribution
[#]Correspondence

Abstract

Serological studies are critical for understanding pathogen-specific immune responses and informing public health measures[1,2]. By developing highly sensitive and specific trimeric spike (S)-based antibody tests, we report IgM, IgG and IgA responses to SARS-CoV-2 in COVID-19 patients (*n*=105) representing different categories of disease severity. All patients surveyed were IgG positive against S. Elevated anti-SARS-CoV-2 antibody levels were associated with hospitalization, with IgA titers, increased circulating IL-6 and strong neutralizing responses indicative of intensive care status. Antibody-positive blood donors and pregnant women sampled during the pandemic in Stockholm, Sweden (weeks 14-25), displayed on average lower titers and weaker neutralizing responses compared to patients; however, inter-individual anti-viral IgG titers differed up to 1,000-fold. To provide more accurate estimates of seroprevalence, given the frequency of *weak responders* and the limitations associated with the dichotomization of a continuous variable[3,4], we used a Bayesian approach to assign likelihood of past infection without setting an assay cut-off. Analysis of blood donors (*n*=1,000) and pregnant women (*n*=900) sampled weekly demonstrated SARS-CoV-2-specific IgG in 7.2% (95% Bayesian CI [5.1 – 9.5]) of individuals two months after the peak of spring 2020 COVID-19 deaths. Seroprevalence in these otherwise healthy cohorts increased steeply before beginning to level-off, following the same trajectory as the Stockholm region deaths over this time period.

Introduction

As SARS-CoV-2 only recently crossed the species barrier[5], populations globally were immunologically naïve to the virus. Characterizing the antibody response to nascent outbreaks is, therefore, central to optimizing approaches to tackle COVID-19 and future pandemics, furthering our basic understanding of human immunology[6–8].

To date, numerous SARS-CoV-2 studies have reported seroprevalence and disease-associated antibody phenotypes[9–11], isolated virus-neutralizing monoclonal antibodies[12–15] and used convalescent individuals to define metrics for plasma therapy[16]. However, consensus on several key issues remains outstanding. For instance, the majority of serology data are derived from commercial kits utilizing SARS-CoV-2 spike derivatives (e.g. RBD, S1 or S2 domains) or the nucleocapsid to detect pathogen-specific antibodies[9,17,18]. Several of these assays suffer from epitope loss[19], increased cross-reactivity[9,20] and lower sensitivity[21], highlighting the need for comparative studies to identify optimal assay formats for individual and population level analysis[22–24]. Here, we developed a highly sensitive and specific ELISA assay based on native-like prefusion-stabilized spike trimers[25], as well as the receptor-binding domain (RBD), to accurately evaluate anti-viral antibody levels in COVID-19 patients and key community groups. To identify disease-associate antibody phenotypes, anti-viral IgM, IgG and IgA levels were analyzed alongside *in vitro* virus neutralisation capacity and a descriptive set of clinical features, including intensive care status.

A major consideration for antibody testing concerns setting the cut-off for positivity[26–28], which significantly affects seroprevalence estimates and individual clinical management. Currently employed approaches to the problem are severely limited by their high dependency on the representative nature of negative control values and the dichotomization of a continuous variable. Therefore, to obtain more accurate seroprevalence estimates in blood donors and pregnant women, we strictly controlled our assay with a large number of historical controls (*n*=295) and used our patient data to train probabilistic algorithms to handle ELISA data. We used our cut-off-independent approach to model population changes in seropositivity over time.

We sampled blood donors and pregnant women weekly throughout the outbreak. Blood donors serve as an important clinical resource, including for potential COVID-19 plasma therapies, while pregnant women require close clinical monitoring with respect to fetal-maternal health and are known to employ unique, yet poorly characterized immunological mechanisms that impact infectious pathology[29–31]. As Sweden did not impose a strict lockdown in response to the pandemic and has reported relatively high per-capita morbidity and mortality (ECDC, EU), understanding

90   SARS-CoV2 seroprevalence in these cohorts helps plan clinical need and understand
91   the development of immunity in the population.
92

Results

Anti-SARS-CoV-2 antibody phenotypes in COVID-19 patients, blood donors and pregnant women

To evaluate humoral immune responses to SARS-CoV-2, we developed ELISA protocols to profile IgM, IgG and IgA directed against a stabilized trimeric form of the spike (S) glycoprotein[25], its receptor binding domain (RBD) and the nucleocapsid protein. The two spike-based antigens were produced in mammalian cells in-house (Fig S1A) and S trimer conformation was confirmed by cryo-EM analysis[32].

The study as a whole, included sera from SARS-CoV-2 PCR-positive COVID-19 patients (*n*=105) representing different disease categories, current blood donors (*n*=1,000) and pregnant women (*n*=900) sampled during 2020, hereafter referred to as healthy donors, historical blood donors collected during spring 2019 (*n*=295) and individuals shown to be PCR+ for endemic coronaviruses (ECV+, *n*=20) (Table 1 and Materials and Methods). We used a subset of these samples as a validation set for assay optimization, comprising samples from COVID-19 patients (*n*=36) and two sets of negative controls, 2019 blood donors (*n*=75) and ECV+ individuals (*n*=20).

All COVID-19 patients in the validation set displayed IgG responses to the S antigen and almost all responded to RBD, albeit less strongly (Fig S1B and S2A). No reactivity was recorded for the negative control samples, except for two ECV+ individuals who displayed reproducible IgM reactivity to SARS-CoV-2 nucleocapsid and S, and two 2019 blood donors with weak anti-S IgM reactivity (Fig S1C and S2). Further investigation is required to establish the basis of these observations and whether cross-reactive memory or primordial lymphocyte lineages contribute to SARS-CoV-2 responses *a priori*.

Our assay revealed up to a 1000-fold difference in anti-viral antibody IgG titers between individuals when examining serially diluted sera (Fig S2). In patients, anti-viral IgG titers were comparable for S (EC_{50}=3,064; 95% CI [1,197 - 3,626]) and nucleocapsid (EC_{50}=2,945; 95% CI [543 - 3,936]) and lower for RBD [EC_{50}=1,751; 95% CI 966 - 1,595]. A subset (approximately 10%) of patients did not have detectable IgG responses to the nucleocapsid (Fig S2), in agreement with previous studies[9].

We next screened all SARS-CoV-2 PCR+ COVID-19 patients in the study (*n*=105) and detected potent IgG responses against S in all individuals and against RBD in all but a 3% individuals (Fig 1A and S3A). When screening the healthy blood donor and pregnant cohorts, we observed a subset of individuals who were clearly seropositive against SARS-CoV-2, but the titers against S and RBD that were generally lower than those measured in COVID-19 patients (Fig 1A and S3A). However, IgG titers in this

135 group varied greatly, with some persons displaying levels similar to those measured
136 in COVID-19 patients while others had titers similar to those observed at the higher
137 end of the historical negative control range. This group of *weak responders* highlighted
138 the challenge of using a pre-determined assay cut-off, a critical point that we address
139 and present potential solutions for in Figure 4.
140
When examining IgM and IgA responses against S and RBD, we found them to be
less potent and more variable between individuals than the IgG response (Fig 1B and
S3B). Given their unique immunological roles and what is known about COVID-19
pathology, we sought to investigate whether isotype responses segregated with
clinical features. Therefore, the COVID-19 patient cohort was classified according to
clinical disease severity: Category 1 – *non-hospitalized*; Category 2 – *hospitalized*;
Category 3 – *intensive care* (on mechanical ventilation) (Table 1).
148
Within-patient anti-S and anti-RBD responses were highly correlated for all three
isotypes (Fig S3C). Furthermore, multivariate analyses showed that increased anti-
viral IgM, IgG and IgA levels significantly correlated with disease severity (Fig 1C, S3D
and S Table 1), in line with the lower titers observed in blood donors and pregnant
women. This was most pronounced for pathogen-specific IgA, suggestive of
advancing mucosal disease[33]. A more severe clinical picture was also strongly
associated with elevated serum IL-6 (Fig 1C), a cytokine that feeds antibody
production[34–37]. IL-6 is dysregulated in polygenic metabolic diseases[38–40] and acute
respiratory distress syndrome (ARDS)[41], which are risk factors for COVID-19-
associated mortality[42,43]. Notably, under univariate analysis, female patients showed
lower anti-viral IgA levels than males in non-hospitalized and hospitalized groups,
which was also true for anti-RBD IgA in multivariate analysis (Fig S4A)[44]. Overall,
severity showed the most consistent relationship with any measure and was the
primary driver of Ig levels.
163
To summarize patient antibody phenotypes, we generated a Spearman's rank
correlation matrix (Fig 2A), which highlights a negative association between patient
date of birth and all dataset features, in-keeping with the worse prognosis for elderly
COVID-19 patients, as well as a lack of association between serum IL-6 and anti-viral
IgM levels, further supporting that levels of the cytokine and IgA mark a protracted,
more severe clinical course. After accounting for the effect of age, sex and days since
PCR+ test, anti-viral IgA titers were approximately 3-fold higher in intensive care vs.
non-hospitalized patients, while IL-6 levels were *ca.* 10-fold increased (Fig 2B).
Notably, we also detected low levels of anti-viral IgA when analyzing a small subset
(*n*=100) of healthy donors from this year (Fig S4B).
174
Critical future studies are required to establish the longevity of immunity to SARS-
CoV-2, including the efficacy of cellular re-call responses, as detectable antibody titers

decline in the absence of antigen[45]. Here, anti-viral IgG levels were maintained two
months post-disease onset/positive PCR test, while IgM and IgA declined (Fig S4C),
in agreement with their circulating $t_{1/2}$[46] and reflecting their diagnostic utility. Patient
serum was collected 6-61 days post-PCR (Fig S4D), with the median time from
symptom onset to PCR test being 5 days. In longitudinal patient samples where we
observed seroconversion, IgM, IgG and IgA peaked with similar kinetics when all three
isotypes developed, although anti-viral IgA was not always generated in Category 1
and 2 patients (Fig 1D and S4E). We note that anti-viral IgM could be maintained two
months post-PCR+/symptom onset (Fig S4E).

We next characterized virus neutralizing antibody responses in patients and healthy
donors, a key parameter for understanding the potential for protective humoral
immune responses and the selection of plasma therapy donors. Using an *in vitro*
pseudotype virus neutralisation assay, we detected neutralizing antibodies in the
serum of all COVID-19 patients, and in all except two healthy antibody-positive donors
(from *n*=56). A range of neutralizing ID_{50} titers is apparent in patients' serum
(geometric mean ID_{50}=1,330; 95% CI [837 − 2,112], Fig 3A), with binding and
neutralisation titers being highly correlated (Fig 2A). The strongest neutralizing
responses were observed in samples from patients in intensive care (Category 3)
(ID_{50}=5,058; 95% CI [2,422 - 10,564]), in keeping with their elevated and presumably
more developed antibody response (Fig 3B and 1C). Sera from healthy blood donors
and pregnant women also displayed neutralizing responses, but similarly to the
binding data, were generally less potent than that observed in COVID-19 patients
(ID_{50}=600; 95% CI [357 − 1,010] and ID_{50}=350; 95% CI [228 - 538], respectively, Fig
3C). Across the two antigens and three isotypes, anti-RBD IgG was most strongly
correlated with neutralization (Fig 3D).

<u>Community seroprevalence estimations</u>

As the Stockholm region is a busy metropolitan area and Sweden did not impose strict
lockdown in response to the emergence of SARS-CoV-2, we sought to better
understand the frequency and nature of anti-SARS-CoV-2 antibody responses in
healthy blood donors and pregnant women during weeks 14-25 (March 30 to June 22
2020) (Fig 4A).

By surveying a large number of historical controls (*n*=295) during assay development,
we identified a considerable number of samples with *weak reactor*-phenotypes, which
must be taken into account when setting the assay cut-off. When using a small set of
historical controls, such values may be missed, resulting in an incorrect cut-off that
significantly increases the uncertainty of individual and population seroprevalence
estimates. To illustrate this, we randomly sampled groups of 20 negative control
samples (from 890 measures in 295 individuals) and calculated seroprevalence in

blood and pregnant women from weeks 17-19 based on a 6SD cut-off. Depending on which 20 negative controls were sampled, the seroprevalence ranged from 5.7 to 8.7%, a 35% difference (Fig 4B). *Weak responder* status is likely influenced by many factors, including genetic background, health status, total serum Ig and protein levels, assay variability. Critically, test samples with low anti-viral titers may also fall into this range, highlighting the need to better understand the assay boundary. Taking a one-dimensional 6SD cut-off for anti-S IgG responses based on all 890 values from 295 negative donors, 7.7% of healthy donors tested positive two months after the peak of deaths in the country (Fig 4C).

To exploit individual antibody titers and improve our estimates, we modelled the probability that a sample is positive by training two parallel learners using our patient and historical control anti-S and -RBD data, rather than setting a one-dimensional cut-off. Our Bayesian approach for inferring seroprevalence without thresholds is described in Christian *et al*[47]. Briefly, we exploit a class-balance corrected Bayesian logistic regression to infer seroprevalence, using a modified Gaussian Process to construct a prior over seroprevalence trajectories, sharing information between weeks. Using this approach, which allowed us to model population changes over time, we found the steep increase in positivity at the start of the pandemic to slow between weeks 17-25, approximating 7.2% (95% equal tailed Bayesian credible intervals [5.1 – 9.5]) at the last time point and suggesting that humoral immunity to the virus develops slowly in these populations despite considerable virus spread in the community.

To confirm our novel Bayesian approach, we compared it to various machine learning algorithms, creating an ensemble SVM-LDA learner to maximize sensitivity, specificity and consistency across different cross-validation strategies, where the proportion of positives in the held-out test set was deliberately varied from the training set (*see* Materials and Methods). We obtained convergent results between these tools and our framework (Fig S5A). Strikingly, seroprevalence inferred using our Bayesian approach exhibited the same trajectory as Stockholm County deaths when lagged by two and half weeks (Fig S5B), allowing for the calculation of a seroprevalence case fatality rate in appropriately powered cohorts.

Furthermore, such probabilistic approaches that annotate uncharacterized uncertainty pave the way towards greater clinical utility for antibody measures. For example, individuals 50% likely to be antibody-positive according to the ensemble learner (Fig 4E) can targeted for further investigation (e.g. re-testing). These tools have the potential, therefore, to provide more qualitative individual antibody measurements.

Discussion

Serology remains the *gold standard* for estimating previous exposure to pathogens and benefits from a large historical literature[48]. When robust, it indicates whether an individual has mounted an adaptive immune response against a specific agent and is a strong predictor of an anamnestic response and quicker recovery upon re-infection. Anti-viral antibody responses are central for protection against re-infection and for the protective efficacy of successful vaccines[49].

Although the concept of herd immunity is based upon the study of antibodies, worryingly, there is little-to-no standardization (or validation) of many of the available SARS-CoV-2 antibody tests. Globally, hospital staff and health authorities are struggling with test choices, negatively impacting individual outcomes and efforts to contain the virus. There is no single ideal test, although some are more accurate, affordable and scalable than others, and it seems reasonable that an international body undertake more basic research-private collaborations to advise on best practice, provide reagents, and further research in the area.

Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 antibody responses in three cohorts of clinical interest. COVID-19 patients showed the highest anti-viral titers, developing augmented serum IgA and IL-6 with worsening disease, likely a consequence of age, sex and other risk factors, as well as prolonged immune stimulation, a higher infectious dose, and host genetics. Therefore, isotype-level measures may assist COVID-19 clinical management and determine, for example, whether all critically ill patients develop class-switched mucosal responses to SARS-CoV-2, potentially informing therapeutic delivery[50,51].

Our neutralisation data shows that patients and healthy donors who seroconvert develop antibody titers capable of preventing infection *in vitro*, demonstrating the beneficial role of immunoglobulins against SARS-CoV-2. Further research into the specific inflammatory molecules/pathways aggravating the disease course, however, would allow for more specific targeting and control of immunity, with IL-6 being a case-in-point (NCT04322773, NCT04359667), although the cytokine's role in orchestrating adaptive responses[52] may make its modulation a double-edged sword in some patients[53].

Outside of the severe disease setting, it is important to determine how many people have seroconverted to SARS-CoV-2. Blood donors and pregnant women are both good sentinels for population health, although they are not enriched for high-risk groups, such as public transportation employees, where rates of infection may be higher. Blood donors are generally working age, active and mobile members of society

302 with a good understanding of health, and the majority of pregnant women in Sweden
303 would have been advised to take precautions against infectious diseases. However,
304 interestingly, both groups showed a similar seroprevalence.
305
By tracking these cohorts over time, we modelled seroprevalence changes at the
population level. We found a steep increase in antibody positivity at the start of the
pandemic, which increased, although at a slower rate, in blood donors and pregnant
women during subsequent weeks, in-line with a decreasing caseload and fatalities[54].
Indeed, ICU occupancy and deaths are a better proxy for viral spread than PCR+
diagnoses, which are highly dependent on the number of tests carried out, and we
note the close approximation of our seroprevalence data to Stockholm County deaths
(Fig S5B), illustrating the power of mortality data to infer seroprevalence and *vice*
versa.
315
Together, our study defines key features of the humoral immune responses to
emerging beta-coronaviruses, delineating disease features, while our seroprevalence
data indicate that population immunity to SARS-CoV-2 develops slowly even in the
absence of lockdowns, suggesting that classical serological herd immunity following
natural infection will require a larger outbreak and higher clinical toll; notwithstanding
yet unknown contributions from T lymphocytes and other lineages. Given the
uniqueness of the approach in Sweden[55], these data may inform the management of
future pandemics. More widely, given the high inter-individual variability in antibody
responses to SARS-CoV-2, the genetic and environmental factors influencing
individual antibody responses will be important to elucidate.
326
327

Materials and methods

Human samples and ethical declaration

Samples from COVID-19 patients (*n*=105) were collected through the Departments of Medicine and Clinical Microbiology at the Karolinska University Hospital and were handled and analyzed in accordance with approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal identifiers were pseudo-anonymized, and clinical feature data were blinded to the researchers carrying out experiments until data generation was complete.

All patients in the study were confirmed PCR+ for SARS-CoV-2 by nasopharyngeal swab or upper respiratory tract sampling after being admitted to Karolinska University Hospital. As viral RNA CT values were determined using different qPCR platforms between patients, we did not analyze these alongside other available features. Patients were questioned about the date of symptom onset at their initial consultation and followed-up for serology during their care, up to 2 months post-diagnosis. In addition, longitudinal samples from 10 of these patients were collected to monitor seroconversion and isotype persistence.

Anonymized samples from blood donors (100/week) and pregnant women (100/week) were randomly selected and obtained from the department of Clinical Microbiology, Karolinska University Hospital. No metadata, such as age or sex information was available for these samples. Pregnant women were sampled as part of routine for infectious diseases screening during the first trimester of pregnancy. Blood donors (*n*=295) collected through the same channels a year previously were randomly selected for use as negative controls. Serum samples from individuals testing PCR+ for endemic coronaviruses, 229E, HKU1, NL63, OC43 (*n*=20, ECV+) in the prior 2-6 months, were used as additional negative controls. The use of these anonymized samples was approved by the Swedish Ethical Review Authority (registration no. 2020-01807).

Stockholm County death and Swedish mortality data was sourced from the ECDC and Swedish Public Health Agency, respectively.

Study samples are defined in Table 1.

Serum sample processing

Blood samples were collected from patients by the attending clinical team and serum isolated by the department of Clinical Microbiology. Samples were barcoded and

369 stored at -20°C until use. Serum samples were not heat-inactivated for ELISA
370 protocols but were heat-inactivated at 56°C for 60 min for neutralization experiments.
371
372 <u>SARS-CoV-2 antigen generation</u>
373
The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain
with a C-terminal T4 fibritin trimerization motif was obtained from[25]. The plasmid was
used to transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent
(Thermo Fisher Scientific). The ectodomain was purified from filtered supernatant on
Streptactin XT resin (IBA Lifesciences), followed by size-exclusion chromatography
on a Superdex 200 in 5 mM Tris pH 8, 200 mM NaCl.
380
381 The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A
382 recognition site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described
383 above. RBD-HIS was purified from filtered supernatant on His-Pur Ni-NTA resin
384 (Thermo Fisher Scientific), followed by size-exclusion chromatography on a Superdex
385 200. The nucleocapsid was purchased from Sino Biological.
386
387 <u>Anti-SARS-CoV2 ELISA</u>
388
96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S, RBD or
nucleocapsid (100 µl of 1 ng/µl) in PBS overnight at 4°C. Plates were washed six times
with 300 ml PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk (Sigma).
Human serum samples were thawed at room temperature, diluted (1:100 unless
otherwise indicated), vortexed and incubated in blocking buffer for 1h before plating.
Serum samples were incubated overnight at 4°C before washing, as before.
Secondary HRP-conjugated anti-human antibodies were diluted in blocking buffer and
incubated with samples for 1 hour at room temperature. Plates were washed a final
time before development with TMB Stabilized Chromogen (Invitrogen). The reaction
was stopped using 1M sulphuric acid and OD values were measured at 450 nm using
an Asys Expert 96 ELISA reader (Biochrom Ltd.). Secondary antibodies (all from
Southern Biotech) and dilutions used: goat anti-human IgG (2014-05) at 1:10,000;
goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA (2050-05) at 1:6,000.
All assays of the same antigen and isotype were developed for their fixed time and
samples were randomized and run together on the same day when comparing binding
between patients. All data were log transformed for statistical analyses.
405
406 *In vitro* virus neutralisation assay
407
Pseudotyped viruses were generated by the co-transfection of HEK293T cells with
plasmids encoding the SARS-CoV-2 spike protein harboring an 18 amino acid
truncation of the cytoplasmic tail[25]; a plasmid encoding firefly luciferase; a lentiviral

packaging plasmid (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was
changed 12-16 hours post-transfection and pseudotyped viruses harvested at 48- and
72-hours, filtered through a 0.45 μm filter and stored at -80°C until use. Pseudotyped
neutralisation assays were adapted from protocols validated to characterize the
neutralization of HIV, but with the use of HEK293T-*ACE2* cells. Briefly, pseudotyped
viruses sufficient to generate ~100,000 RLUs were incubated with serial dilutions of
heat-inactivated serum for 60 min at 37°C. Approximately 15,000 HEK293T-ACE2
cells were then added to each well and the plates incubated at 37°C for 48 hours.
Luminescence was measured using Bright-Glo (Promega) according to the
manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration
time of 0.3s. The limit of detection was at a 1:45 serum dilution.
422
423 <u>IL-6 cytometric bead array</u>
424
425 Serum IL-6 levels were measured in a subset of PCR+ COVID-19 patient serum
426 samples (*n*=64) using an enhanced sensitivity cytometric bead array against human
427 IL-6 from BD Biosciences (Cat # 561512). Protocols were carried out according to the
428 manufacturer's recommendations and data acquired using a BD Celesta flow
429 cytometer.
430
431 <u>Statistical analysis of patient data</u>
432
All univariate comparisons were performed using non-parametric analyses (Kruskal-
Wallis, stratified Mann-Whitney, hypergeometric exact tests and Spearman rank
correlation), as indicated, while multivariate comparisons were performed using linear
regression of log transformed measures and Wald tests. For multivariate tests, all
biochemical measures (IL-6, PSV ID50 neut., IgG, IgA, IgM) were log transformed to
improve the symmetry of the distribution. As "days since first symptom" and "days
since PCR+ test" are highly correlated, we cannot include both in any single analysis.
Instead, we show results for one, then the other (Supplementary Table 1).
441
442 <u>Probabilistic seroprevalence estimations</u>
443
We employed two distinct probabilistic strategies for estimating seroprevalence
without thresholds, each developed independently. Our Bayesian approach is
explained in detail in Christian *et al*[47]. Briefly, we use a logistic regression over anti-
RBD and -S training data to model the relationship between the ELISA measurements
and the probability that a sample is antibody-positive. We adjust for the training data
class proportions and use these adjusted probabilities to inform the seroprevalence
estimates for each time point. Given that the population seroprevalence cannot
increase dramatically from one week to the next, we construct a prior over
seroprevalence trajectories using a transformed Gaussian Process, and combine this

with the individual class-balance adjusted infection probabilities for each donor to infer
the posterior distribution over seroprevalence trajectories.
455
Our second approach was based on more traditional machine learning and statistical
approaches, which we compared through ten-fold cross validation (CV): logistic
regression, linear discriminant analysis (LDA), and support vector machines (SVM)
with a linear kernel. Logistic regression and linear discriminant analysis both model
log odds of a sample being case as a linear equation with a resulting linear decision
boundary. The difference between the two methods is in how the coefficients for the
linear models are estimated from the data. When applied to new data, the output of
logistic regression and LDA is the probability of each new sample being a case.
464
Support vector machines is an altogether different approach. We opted for a linear
kernel, once again resulting in a linear boundary. SVM constructs a boundary that
maximally separates the classes (i.e. the margin between the closest member of any
class and the boundary is as wide as possible), hence points lying far away from their
respective class boundaries do not play an important role in shaping it. SVM thus puts
more weight on points closest to the class boundary, which in our case is far from
being clear. Linear SVM has one tuning parameter C, a cost, with larger values
resulting in narrower margins. We tuned C on a vector of values (0.001, 0.01, 0.5, 1,
2, 5, 10) via an internal 5-fold CV with 5 repeats (with the winning parameter used for
the final model for the main CV iteration). We also note that the natural output of SVM
are class labels rather than class probabilities, so the latter are obtained via the
method of Platt[56].
477
478 We considered three strategies for cross-validation:
479
• random: individuals were sampled into folds at random
• stratified: individuals were sampled into folds at random, subject to ensuring
the balance of cases:controls remained fixed
• unbalanced : individuals were sampled into folds such that each fold was
deliberately skewed to under or over-represent cases compared to the total
sample
486
487 We sought a method that worked equally well across all cross-validation schemes, as
488 the true proportion of cases in the test data is unknown and so a good method should
489 not be overly sensitive to the proportion of cases in the training data.
490
491 We found most methods worked well, although logistic regression was sensitive to
492 changes in the case proportion in the training data. We chose to create an ensemble
493 method combining that with the highest specificity (LDA) and the highest sensitivity
494 (SVM), defined as an unweighted average of the probabilities generated under SVM

and LDA. The ensemble learner had average sensitivity > 99.1% and average specificity 99.8%.

We then trained the ensemble learner on all 719 training samples and predicted the probability of anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. We inferred the proportion of the sampled population with positive antibody status each week using multiple imputation. We repeatedly (1,000 times) imputed antibody status for each individual randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets in parallel, combining inference using Rubin's rules, derived for the Wilson binomial proportion confidence interval[57].

Data and code availability statement

Data generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.

Author contributions

GKH and XCD designed the study, analyzed the results and wrote the manuscript with input from co-authors. JA, TA, SM, GB and SA provided the study serum samples and clinical information. LH, LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and pseudotyped viruses. XCD and MF developed the ELISA protocols and XCD generated the data. DJS and BM developed and performed the neutralization assay. MCh and BM developed the Bayesian framework. CW and NFG assisted with patient data statistical analyses and executed machine learning approaches. MA, SK, PP, MM, JC, MCo and JR carried out wet lab experiments and assisted with data analysis.

Acknowledgments

We would like to thank the study participants and attending clinical teams. Secondly, we extend our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis Sayago for their input and discussion. Funding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)

Conflict of interest

537   The study authors declare no competing interests related to the work.

538   **References**

540   1.   Altman, D., Douek, D. & Boyton, R. What policy makers need to know about
541   COVID-19   protective   immunity.   *Lancet*   (2020)
542   doi:https://doi.org/10.1016/S0140-6736(20)30985-5.
543   2.   Mouquet, H. & Nussenzweig, M. C. Polyreactive antibodies in adaptive immune
544   responses to viruses. *Cellular and Molecular Life Sciences* (2012)
545   doi:10.1007/s00018-011-0872-6.
546   3.   MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of
547   dichotomization of quantitative variables. *Psychol. Methods* (2002)
548   doi:10.1037//1082-989x.7.1.19.
549   4.   Altman, D. G. & Royston, P. The cost of dichotomising continuous variables.
550   *British Medical Journal* (2006) doi:10.1136/bmj.332.7549.1080.
551   5.   Zhu, N. *et al.* A novel coronavirus from patients with pneumonia in China, 2019.
552   *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2001017.
553   6.   Davis, M. M. A Prescription for Human Immunology. *Immunity* vol. 29 835–838
554   (2008).
555   7.   Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19
556   control. *The Lancet Infectious Diseases* (2020) doi:10.1016/S1473-
557   3099(20)30322-4.
558   8.   London, A. J. & Kimmelman, J. Against pandemic research exceptionalism.
559   *Science* (2020) doi:10.1126/SCIENCE.ABC1731.
560   9.   Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-
561   19. *Nat. Med.* (2020) doi:10.1038/s41591-020-0897-1.
562   10.   Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel
563   coronavirus disease 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/ciaa344.
564   11.   Tan, W. *et al.* Viral Kinetics and Antibody Responses in Patients with COVID-
565   19. *J Clin* **doi: 10.11**, (2020).
566   12.   Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection
567   in Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
568   13.   Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients
569   define multiple targets of vulnerability. *Science (80-.).* (2020)
570   doi:10.1126/science.abc5902.
571   14.   Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection.
572   *Nature* (2020) doi:10.1038/s41586-020-2380-z.
573   15.   Seydoux, E. *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals
574   Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
575   *Immunity* (2020) doi:10.1016/j.immuni.2020.06.001.
576   16.   Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-
577   19 patients. *Proc. Natl. Acad. Sci. U. S. A.* (2020)
578   doi:10.1073/pnas.2004168117.
579   17.   Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and
580   Other Human Coronaviruses. *Trends in Immunology* (2020)
581   doi:10.1016/j.it.2020.03.007.
582   18.   Van Elslande, J. *et al.* Diagnostic performance of seven rapid IgG/IgM antibody
583   tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin. Microbiol.*

Infect. (2020) doi:10.1016/j.cmi.2020.05.023.

19. Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein. *Cell* (2020) doi:10.1016/j.cell.2020.02.058.

20. Cheng, M. *et al.* Cross-reactivity of antibody against SARS-coronavirus
nucleocapsid protein with IL-11. *Biochem. Biophys. Res. Commun.* (2005)
doi:10.1016/j.bbrc.2005.10.088.

21. Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked.
J. Allergy Clin. Immunol. (2020) doi:10.1016/j.jaci.2020.05.020.

22. GeurtsvanKessel, C. H. *et al.* Towards the next phase: evaluation of serological
assays for diagnostics and exposure assessment. *Nat Comms* **doi: 10.10**,
(2020).

23. Deeks, J. J. *et al.* Antibody tests for identification of current and past infection
with SARS-CoV-2. *Cochrane Database Syst. Rev.* (2020)
doi:10.1002/14651858.cd013652.

24. Traugott, M. *et al.* Performance of Severe Acute Respiratory Syndrome
Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of
Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests. *J. Infect.*
Dis. (2020) doi:10.1093/infdis/jiaa305.

25. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation. *Science (80-.).* (2020) doi:10.1126/science.aax0902.

26. Saraswati, K., Phanichkrivalkosil, M., Day, N. P. J. & Blacksell, S. D. The validity
of diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG
ELISAs: A review of the evidence. *PLoS Negl. Trop. Dis.* (2019)
doi:10.1371/journal.pntd.0007158.

27. Xu, H., Lohr, J. & Greiner, M. The selection of ELISA cut-off points for testing
antibody to Newcastle disease by two-graph receiver operating characteristic
(TG-ROC) analysis. *J. Immunol. Methods* (1997) doi:10.1016/S0022-
1759(97)00128-2.

28. Greiner, M., Franke, C. R., Böhning, D. & Schlattmann, P. Construction of an
intrinsic cut-off value for the sero-epidemiological study of Trypanosoma evansi
infections in a canine population in Brazil: a new approach towards an unbiased
estimation of prevalence. *Acta Trop.* (1994) doi:10.1016/0001-706X(94)90044-
2.

29. Aghaeepour, N. *et al.* An immune clock of human pregnancy. *Sci. Immunol.*
(2017) doi:10.1126/sciimmunol.aan2946.

30. Mor, G. & Cardenas, I. The Immune System in Pregnancy: A Unique
Complexity. *American Journal of Reproductive Immunology* (2010)
doi:10.1111/j.1600-0897.2010.00836.x.

31. Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. *New*
England Journal of Medicine (2014) doi:10.1056/NEJMra1213566.

32. Hanke, L. *et al.* An alpaca nanobody neutralizes SARS-CoV-2 by blocking
receptor interaction. *bioRxiv* (2020) doi:10.1101/2020.06.02.130161.

33. Cervia, C. *et al.* Systemic and mucosal antibody secretion specific to SARS-
CoV-2 during mild versus severe COVID-19. *bioRxiv* (2020)
doi:10.1101/2020.05.21.108308.

34. Eto, D. *et al.* IL-21 and IL-6 are critical for different aspects of B cell immunity
and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation.
PLoS One **6**, e17739 (2011).

35. Dienz, O. *et al.* The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4 + T cells. *J. Exp. Med.* (2009) doi:10.1084/jem.20081571.

36. Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. *Blood* (2010) doi:10.1182/blood-2009-07-230631.

37. Beagley, K. W. *et al.* Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. *J. Exp. Med.* (1989) doi:10.1084/jem.169.6.2133.

38. Mauer, J. *et al.* Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. *Nat. Immunol.* (2014) doi:10.1038/ni.2865.

39. Kristiansen, O. P. & Mandrup-Poulsen, T. Interleukin-6 and diabetes: The good, the bad, or the indifferent? *Diabetes* (2005) doi:10.2337/diabetes.54.suppl_2.S114.

40. Ferreira, R. C. *et al.* Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases. *PLoS Genet.* **9**, (2013).

41. Park, W. Y. *et al.* Cytokine balance in the lungs of patients with acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* (2001) doi:10.1164/ajrccm.164.10.2104013.

42. Magro, G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine: X* (2020) doi:10.1016/j.cytox.2020.100029.

43. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. *Nat. Biotechnol.* (2020) doi:10.1038/s41587-020-0602-4.

44. Jin, J. M. *et al.* Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front. Public Heal.* (2020) doi:10.3389/fpubh.2020.00152.

45. Takaki, A. *et al.* Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. *Nat. Med.* (2000) doi:10.1038/75063.

46. Schroeder, H. W. & Cavacini, L. Structure and function of immunoglobulins. *J. Allergy Clin. Immunol.* (2010) doi:10.1016/j.jaci.2009.09.046.

47. Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without Cutoffs. *BioRxiv* (2020).

48. Behring & Kitasato. Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. *Dtsch. Medizinische Wochenschrift* (1890) doi:10.1055/s-0029-1207589.

49. Plotkin, S. A. Vaccines: Correlates of Vaccine-Induced Immunity. *Clin. Infect. Dis.* (2008) doi:10.1086/589862.

50. Larios Mora, A. *et al.* Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. *MAbs* (2018) doi:10.1080/19420862.2018.1470727.

51. Sheridan, C. Ablynx's nanobody fragments go places antibodies cannot. *Nat. Biotechnol.* (2017) doi:10.1038/nbt1217-1115.

52. Hurst, S. M. *et al.* IL-6 and its soluble receptor orchestrate a temporal switch in
the pattern of leukocyte recruitment seen during acute inflammation. *Immunity*
14, 705–714 (2001).
53. Pedersen, B. K. IL-6 signalling in exercise and disease. in *Biochemical Society*
Transactions (2007). doi:10.1042/BST0351295.
54. Intensivvårdsregistret, S. Antal som intensivvårdas med Covid-19 per dag.
Svenska Intensivvårdsregistrets utdataportal
https://portal.icuregswe.org/siri/report/corona.co (2020).
55. Paterlini, M. 'Closing borders is ridiculous': the epidemiologist behind Sweden's
controversial coronavirus strategy. *Nature* (2020) doi:10.1038/d41586-020-
01098-x.
56. Platt, J. & others. Probabilistic outputs for support vector machines and
comparisons to regularized likelihood methods. *Adv. large margin Classif.*
(1999).
57. Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With
Multiple Imputation for Missing Data. *Am. Stat.* (2020)
doi:10.1080/00031305.2018.1473796.
697

Figure 1: Patient, blood donor and pregnant women anti-SARS-CoV-2 antibody phenotypes

(**A**) Log transformed anti-S and -RBD IgG responses are shown in COVID-19 patients (*n*=105), blood donors (BD, *n*=1,000) and pregnant women (PW, *n*=900). Controls (C) represent *n*=295 individuals analyzed repeatedly (to *n*=890). (**B**) IgM, IgG and IgA responses against S and RBD in COVID-19 patients (*n*=105), with a limited number of controls for each assay represented by open circles. (**C**) COVID-19 patient (*n*=105) anti-viral antibody levels and serum IL-6 levels according to clinical disease severity. S and RBD responses are graphed together, alongside a limited number of controls. (**D**) Three longitudinal patient profiles of seroconversion and neutralisation capacity are shown in hospitalized individuals.

Figure 2: Antibody-clinical feature associations in COVID-19 patients
(**A**) Spearman's rank correlation of patient dataset features and antibody levels. DOB - *date of birth*; d-p SymO - *days post-symptom onset*; d-p PCR – *days post SARS-CoV-2+ PCR*; PSV ID50 – *neutralizing titer* (**B**) Adjusted fold change for dataset features in COVID-19 patients compared to category 1 individuals. The effects of age (DOB), sex, days from PCR test were considered.

Figure 3: *In vitro* virus neutralizing responses
(**A**) Pseudotyped virus neutralization by serial dilutions of serum from COVID-19 patients (*n*=48, *red*), blood donors (*blue*) and pregnant women (*purple*). (**B**) Neutralization ID_{50} titers according to disease severity category. (**C**) Comparison of neutralization ID_{50} titers between patients, blood donors and pregnant women. (**D**) Correlation between anti-S and -RBD IgM, IgG and IgA antibodies and neutralisation titers.

Figure 4: Probability-based seroprevalence in Stockholm during the height of the pandemic

(**A**) Study sample collection intervals are shown alongside the rolling weekly average COVID-19 deaths per million inhabitants in relevant countries for comparison. (**B**) By randomly selecting six groups of 20 negative controls from a pool of 890 values (from n=295 individuals), the range of the 6SD cut-off is shown to significantly affect positivity estimates in healthy donors (HD) from weeks 17-19 2020. (**C**) Using a conventional 6SD cut-off, we found 6.2, 6.5 and 7.7% of healthy donors to be antibody-positive in weeks 17-19, 20-22 and 23-25, respectively. (**D**) Seroprevalence estimates in healthy donor cohorts through time using a cut-off-independent Bayesian approach. (**E**) An ensemble SVM-LDA learner trained on our patient data illustrates the problem of weak responders and provides a multi-dimensional solution by providing individual datapoints with a likelihood of positivity, a feature with potential for clinical use.

Table 1 – Study patient, blood donor and pregnant women characteristics

COVID-19 patients (n=)		105
Females		44 (41.9%)
Males		61 (58.1%)
Median age (years)*		53.0 (49-61)
	Females	51.5 (48-56.2)
	Males	55.0 (49-63)
Non-hospitalized		53 (50.5%)
	Females, males	28, 25
Hospitalized		31 (29.5%)
	Females, males	12, 17
Intensive care (ICU)		21 (20%)
	Females, males	3, 17
Disease category unknown		2 (1.9%)
	Females, males	1, 1
SARS-CoV2+ PCR		105
Sample collection dates		February-June 2020
Blood donors (n=)		1,000
Median age (years)		N/A
Sex		N/A
SARS-CoV2+ PCR		N/A
Sample collection dates		Weeks 14-25 2020
Pregnant women (n=)		900
Age (years)		N/A
SARS-CoV2+ PCR		N/A
Sample collection dates		Weeks 17-25 2020
Historical blood donors (n=)		295
Median age (years)		N/A
Sex		N/A
SARS-CoV2+ PCR		No
Sample collection dates		Spring 2019
LQR-UQR given in brackets		

Table 1

Figure S1: Anti-SARS-CoV-2 ELISA protocol development

(**A**) Trimeric S and RBD were expressed in 293F cells and purified as described. (**B**) A subset of patients and negative controls was used to validate the assays for the three isotypes. (**C**) Two ECV+ donors, K2 and K4, showed reproducible IgM binding to S, please refer to their increased responses to S and nucleocapsid in S2. Testing another subset of historical controls (*n*=75) for a similar observation, two additional individuals were found to show IgM binding to S.

Figure S2: Patient binding titrations

A subset (*n*=40) PCR+ COVID-19 patients were titrated in our assay. Shown are these responses against the three antigens and isotypes in the study. Four ECV+ (red lines) were in a similar dilution series alongside.

Figure S3: Healthy donor and patient antibody phenotypes

(**A**) Raw OD450 anti-S and -RBD IgG responses are shown for patients and healthy donors. (**B**) Raw OD450 isotypic responses in patients against S and RBD. A limited number of negative controls are depicted by clear circles. (**C**) Anti-S vs -RBD responses in COVID-19 patients are highly correlated. (**D**) Log transformed patient anti-S and -RBD levels according to disease severity by isotype. *P* values from a Cuzick test for trend.

Figure S4: Patient antibody phenotypes

(**A**) Antibody responses according to sex are shown (left panel) and severity (right panel). *P* values from a Kruskal Wallis or stratified Mann-Whitney, as shown. (**B**) Lower levels of IgA were observed in a subset (*n*=100) of blood donors and pregnant women. Patient (P) and healthy donor (HD) responses to S and RBD are shown. (**C**) IgM and IgA titers declined with time from first symptom/SARS-CoV-2+ PCR and admittance to care. IgG levels were maintained. *P* values from a Spearman rank correlation test. (**D**) Patient sampling according to date since PCR+ test shown for anti-viral IgM responses. (**E**) Longitudinal profiles of category 1 and 2 patients after seroconversion.

Figure S5: Comparison of cut-off-independent machine learning methods

(**A**) Overlay and agreement of SVM-LDA ensemble learner predictions with our Bayesian framework. (**B**) Seroprevalence changes over time follow a very similar trajectory to Stockholm County deaths when lagged by 2.5 weeks.